

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 16, 2023

Conference Call and Webcast at 8:30AM Eastern Time

NEW YORK, May 5, 2023 /PRNewswire/ -- **Lucid Diagnostics Inc. (Nasdaq: LUCD)** ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Tuesday, May 16, 2023, at 8:30 AM EST. During the call, [Lishan Aklog, M.D.](#), Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and growth strategy. In addition, [Dennis McGrath](#), Lucid's Chief Financial Officer, will discuss the Company's first-quarter 2023 financial results.

The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-877-870-4263 and international listeners should dial 1-412-317-0790. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.

About Lucid Diagnostics

Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's [EsoGuard® Esophageal DNA Test](#), performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients.

For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

SOURCE Lucid Diagnostics

For further information: Investor and Media, Michael Parks, PAVmed and Lucid Diagnostics, 484.356.7105, mep@pavmed.com

<https://ir.luciddx.com/2023-05-05-Lucid-Diagnostics-to-Hold-a-Business-Update-Conference-Call-and-Webcast-on-May-16,-2023>